Company description

AQST is an innovative pharmaceutical company that specializes in developing unique and novel treatments for a variety of diseases. Founded in 2017, the company's focus lies primarily on the development and commercialization of its proprietary drugs for treating neurological and psychiatric disorders. With a mission to improve patients' lives through effective and safe treatments, AQST has built a robust pipeline of potential therapies targeting conditions such as Parkinson's disease, epilepsy, and opioid addiction. The company's most advanced product, Libervant, is a sublingual film intended for the treatment of seizure clusters and breakthrough seizures in patients with epilepsy. AQST is also actively pursuing partnerships and collaborations to accelerate the development and regulatory approval process for their innovative therapies. With a team of experienced and dedicated professionals, a strong financial position, and a clear vision for the future, AQST is poised for significant growth and success in the pharmaceutical industry.